Cardiovascular

Heart failure with reduced ejection fraction: outpatient GDMT optimization

Clinical Overview and When to Suspect HFrEF

— HFmrEF: LVEF 41–49% (managed increasingly like HFrEF)

— HFpEF: LVEF ≥50%

— Dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, fatigue, reduced exercise tolerance

— Lower extremity edema, weight gain, abdominal fullness, early satiety

— Post-MI patient with new exertional symptoms or asymptomatic LV dysfunction on surveillance echo

— Patient with cardiotoxic exposure (anthracyclines, trastuzumab, alcohol, methamphetamine, prior chest XRT)

— Family history of dilated cardiomyopathy, peripartum cardiomyopathy history, prior viral myocarditis

— Stage A: at risk (HTN, DM, CAD, family hx) — no structural disease

— Stage B: structural disease (low EF, prior MI) but asymptomatic — still start ACEi/ARB + beta-blocker

— Stage C: structural disease with current or prior symptoms — full GDMT

— Stage D: refractory/advanced — transplant, LVAD, palliative inotropes, hospice

Definition: Heart failure with reduced ejection fraction (HFrEF) = clinical HF syndrome plus LVEF ≤40% on imaging

Epidemiology and stakes: ~6.7 million US adults with HF; HFrEF accounts for ~50%. 5-year mortality remains ~50% despite therapy. Optimization of guideline-directed medical therapy (GDMT) in the outpatient setting is the single highest-yield intervention for mortality, hospitalization, and quality of life.

When to suspect HFrEF in clinic:

ACC/AHA stages (longitudinal framework Step 3 loves):

Step 3 management: A patient with LVEF 35% after anterior MI but no symptoms is Stage B — they still need ACEi/ARB/ARNI and evidence-based beta-blocker, plus ICD evaluation at ≥40 days post-MI if EF remains ≤35%.

Board pearl: Step 3 vignettes frequently test transition from inpatient discharge to outpatient titration: the patient leaves the hospital on low-dose GDMT, and your job is to up-titrate every 1–2 weeks to target or maximally tolerated doses within 3–6 months.

Presentation Patterns and Key History

— Dyspnea: quantify in METs or block-equivalents; ask about change from baseline

— Orthopnea: number of pillows, sleeping in recliner

— PND: waking gasping 1–3 hours after sleep

— Bendopnea: dyspnea on bending forward (tying shoes) — correlates with elevated filling pressures

— Fatigue / reduced exercise tolerance — often dominant in younger patients

— Edema, weight gain (>2 lb/day or >5 lb/week), abdominal bloating, anorexia, RUQ discomfort (hepatic congestion)

— I: no limitation

— II: symptoms with ordinary activity

— III: symptoms with less than ordinary activity

— IV: symptoms at rest

— Ischemic: prior MI, angina, CAD risk factors → revascularization workup

— Hypertensive: long-standing uncontrolled HTN

— Valvular: AS, AR, MR — may need surgical/TAVR referral

— Toxic: alcohol (quantify), cocaine/meth, anthracyclines, trastuzumab, immune checkpoint inhibitors, chest radiation

— Infiltrative: amyloidosis (carpal tunnel bilateral, low-voltage ECG with thick walls), sarcoid (AV block, young patient)

— Genetic: family history of HF, sudden death, DCM

— Peripartum: within last month of pregnancy through 5 months postpartum

— Tachycardia-mediated: chronic AF with RVR, frequent PVCs >10–20% burden

— Dietary sodium, fluid intake, medication adherence, NSAID use, recent steroid bursts, missed dialysis, new AF, ischemia, infection, pregnancy, thyroid dysfunction

Cardinal symptoms (probe systematically):

NYHA functional class (drives therapy decisions and trial eligibility):

Targeted etiology history (changes management):

Adherence and trigger history (CCS-style outpatient visit):

Key distinction: Acute decompensation is almost always triggered — "FAILURE" mnemonic (Forgot meds, Arrhythmia/Anemia, Ischemia/Infection/Infarction, Lifestyle/salt, Upregulation (thyroid/pregnancy), Renal failure, Embolus/Endocarditis). On Step 3, identify and reverse the trigger before escalating GDMT.

Step 3 management: A patient missing 1 week of furosemide due to cost → social work referral + 90-day generic supply, not immediate dose escalation.

Physical Exam Findings and Hemodynamic Assessment

— Narrow pulse pressure (<25% of SBP) suggests low cardiac output

— Resting tachycardia, low SBP (<90) → concerning for cardiogenic shock

— Cheyne-Stokes respirations in advanced HF

— Wet (congested): elevated JVP (>8 cm above sternal angle, or visible above clavicle while sitting), hepatojugular reflux, S3 gallop, rales, peripheral edema, ascites, hepatomegaly, pulsatile liver

— Dry: no congestion findings

— Warm (adequate perfusion): warm extremities, normal mentation, adequate urine output

— Cold (low output): cool/mottled extremities, narrow pulse pressure, hypotension, altered mentation, oliguria, hyponatremia

— A (warm/dry): optimize chronic GDMT

— B (warm/wet): most common ED presentation — IV diuresis

— C (cold/wet): diuresis + inotropes/vasodilators; consider ICU

— L (cold/dry): rare — usually need careful filling or advanced therapies

— S3 gallop: rapid ventricular filling against stiff/dilated ventricle — most specific exam finding for HF

— Laterally displaced PMI: LV dilation

— Holosystolic murmur at apex radiating to axilla: functional MR from annular dilation

— Pulsus alternans: alternating strong/weak pulse — severe LV dysfunction

— Kussmaul sign: JVP rises on inspiration — suggests constrictive physiology or RV failure

Vital signs:

Volume status (the "wet/dry, warm/cold" framework — high-yield):

Four profiles drive therapy:

Specific findings:

CCS pearl: In the CCS case of outpatient HF follow-up, your first orders should include vitals (orthostatics), weight (compare to dry weight), JVP assessment, lung auscultation, and lower extremity edema check — these guide whether to up-titrate GDMT (euvolemic) or first achieve euvolemia with diuretics.

Board pearl: JVP and S3 carry the highest likelihood ratios for elevated filling pressures. A patient with JVP at 12 cm and an S3 is wet regardless of weight — adjust diuretic before next GDMT titration step.

Diagnostic Workup — Initial Labs, Imaging, ECG, Biomarkers

— BNP >35 pg/mL or NT-proBNP >125 pg/mL (ambulatory cutoffs) support HF diagnosis

— Higher cutoffs in acute setting: BNP >100, NT-proBNP age-adjusted (>450 if <50, >900 if 50–75, >1800 if >75)

— Falsely low: obesity, ARNI use (BNP rises with sacubitril/valsartan; use NT-proBNP instead — not cleaved by neprilysin)

— Falsely high: age, female sex, renal dysfunction, AF, sepsis, PE

— CBC (anemia worsens HF), CMP (Na, K, creatinine, LFTs — congestive hepatopathy), glucose/A1c

— TSH (both hyper- and hypothyroidism cause HF)

— Iron studies: ferritin and transferrin saturation — iron deficiency in 50% of HFrEF; IV iron (ferric carboxymaltose) improves symptoms even without anemia if ferritin <100 or 100–300 with TSAT <20%

— Lipid panel, HIV (if risk factors), fasting glucose

— Consider: SPEP/UPEP/free light chains if amyloid suspected; HIV; iron sat for hemochromatosis

— LVH, prior Q waves (ischemic etiology), LBBB (CRT candidate if QRS ≥150 ms), AV block (sarcoid, Lyme, amyloid), low voltage with pseudo-infarct pattern (amyloid)

— Quantifies LVEF, chamber sizes, wall motion abnormalities, valvular disease, RV function, estimated PA pressures, diastolic function

— Repeat TTE at 3–6 months after GDMT optimization to reassess EF and ICD candidacy

Natriuretic peptides (essential):

Baseline labs (every new HF and at follow-up):

ECG (every patient):

Chest X-ray: cardiomegaly, cephalization, Kerley B lines, pleural effusions, pulmonary edema

Transthoracic echocardiogram (TTE) — the diagnostic cornerstone:

Step 3 management: Newly diagnosed HFrEF → order BNP/NT-proBNP, TTE, ECG, CBC, CMP, TSH, iron studies, A1c, lipids, HIV. Do NOT routinely order endomyocardial biopsy.

Board pearl: Natriuretic peptides are most useful when negative — a normal BNP/NT-proBNP in an untreated dyspneic patient effectively rules out HF (high NPV).

Diagnostic Workup — Advanced or Confirmatory Studies

— Coronary angiography is reasonable in any new HFrEF patient with angina or significant ischemia risk to identify revascularizable disease

— CT coronary angiography acceptable alternative in lower-risk patients

— Stress imaging (stress echo, nuclear, stress CMR) for intermediate probability

— Why it matters: revascularization of viable hypocontractile myocardium can recover EF (STICH trial showed CABG benefit in ischemic HFrEF)

— Best test for etiology when echo is non-diagnostic

— Late gadolinium enhancement patterns:

— — Subendocardial/transmural → ischemic

— — Mid-wall striae → nonischemic DCM

— — Patchy/epicardial → myocarditis or sarcoid

— — Diffuse subendocardial with difficulty nulling myocardium → amyloid

— Amyloid: technetium pyrophosphate (PYP) scan for ATTR; SPEP/UPEP/free light chains to exclude AL (must be done first — AL is hematologic emergency)

— Sarcoid: cardiac PET, CMR; consider endomyocardial biopsy in select cases

— Hemochromatosis: iron studies, HFE gene testing, CMR T2*

— Genetic DCM: consider testing if family history or specific phenotype (LMNA, TTN)

— Hypertrophic cardiomyopathy with reduced EF (burned-out HCM): genetic testing

— VO2 max <14 mL/kg/min (or <12 if on beta-blocker) = transplant evaluation threshold

— Distinguishes cardiac vs pulmonary limitation

— Indicated for advanced HF evaluation (transplant/LVAD workup), suspected pulmonary hypertension out of proportion, unclear volume status, or guiding therapy in refractory cases

Ischemic evaluation (mandatory in new HFrEF):

Cardiac MRI (CMR):

Specialized testing by suspicion:

Cardiopulmonary exercise testing (CPET):

Right heart catheterization:

Key distinction: Endomyocardial biopsy is NOT routine — reserved for suspected giant cell myocarditis, eosinophilic myocarditis, cardiac sarcoid, or unexplained rapidly progressive HF when results would change management.

Step 3 management: New HFrEF + bilateral carpal tunnel + thick LV walls on echo + low-voltage ECG → rule out AL amyloid with SPEP/UPEP/serum free light chains FIRST, then PYP scan for ATTR.

Risk Stratification and First-Line Management Logic

— 1. ARNI (sacubitril/valsartan) — or ACEi/ARB if ARNI not feasible

— 2. Evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol)

— 3. MRA (spironolactone or eplerenone)

— 4. SGLT2 inhibitor (dapagliflozin or empagliflozin) — regardless of diabetes status

— Each provides independent mortality reduction

— Combined therapy yields ~73% relative reduction in cardiovascular death vs. conventional therapy

— Benefit accrues within 30 days of initiation

— Old paradigm of "start one, titrate to target, then add next" delayed benefit by 6–12 months

— Initiate all 4 classes at low doses within days to 2 weeks

— Up-titrate every 1–2 weeks based on BP, HR, K, creatinine, symptoms

— Target maximum tolerated or guideline doses by 3–6 months

— Close follow-up (1–2 weeks) until stable

— Seattle Heart Failure Model, MAGGIC score, MECKI score estimate 1- and 5-year mortality

— Triggers for advanced therapy referral (mnemonic I-NEED-HELP): IV inotropes, NYHA III/IV with persistent symptoms, End-organ dysfunction, EF <35%, Defibrillator shocks, Hospitalizations >1/year, Edema despite escalating diuretics, Low BP/high HR, Prognostic medication intolerance

Foundational principle of modern HFrEF care: the "four pillars" (quadruple therapy) — start ALL FOUR early and titrate in parallel, not sequentially

Why all four early?

Modern STRONG-HF-style approach:

Risk stratification tools:

Step 3 management: Patient discharged after first HFrEF admission (EF 25%) on low-dose ACEi and beta-blocker → at 2-week follow-up, switch ACEi to ARNI (after 36-hour washout), add MRA if K <5 and eGFR >30, add SGLT2i, and schedule next visit in 1–2 weeks for up-titration.

Board pearl: Step 3 will reward you for simultaneous initiation and aggressive early titration over sequential approach. Document the plan and follow-up cadence.

Pharmacotherapy — First-Line Drug Regimen

— Sacubitril/valsartan: start 24/26 mg or 49/51 mg BID; target 97/103 mg BID

— Switching from ACEi: requires 36-hour washout to avoid angioedema (no washout from ARB)

— Contraindications: history of angioedema, pregnancy, bilateral RAS, K >5.2, SBP <100

— ACEi alternatives: enalapril (target 10–20 mg BID), lisinopril (20–40 mg daily)

— ARB if ACEi intolerant (cough): losartan 150 mg daily, valsartan 160 mg BID

— Carvedilol 3.125 mg BID → target 25 mg BID (50 mg BID if >85 kg)

— Metoprolol succinate (XL) 12.5–25 mg daily → target 200 mg daily

— Bisoprolol 1.25 mg daily → target 10 mg daily

— Start only when euvolemic; double dose every 2 weeks as tolerated

— Do NOT abruptly discontinue — risk of rebound tachycardia/decompensation

— Spironolactone 12.5–25 mg daily → target 25–50 mg

— Eplerenone if gynecomastia from spironolactone

— Requires K ≤5.0 and eGFR ≥30 at initiation; recheck K and Cr at 1 week, 1 month, then q3 months

— Dapagliflozin 10 mg daily or empagliflozin 10 mg daily — fixed dose, no titration

— Benefit independent of diabetes status; safe down to eGFR 20

— Counsel on euglycemic DKA risk, genital mycotic infections, volume; hold during sick days/surgery

— Hydralazine + isosorbide dinitrate: add for self-identified Black patients with NYHA III–IV on optimal GDMT (A-HeFT); also if ACEi/ARB/ARNI contraindicated

— Ivabradine: NSR + HR ≥70 on max beta-blocker (SHIFT)

— Vericiguat: recent worsening HF event despite GDMT (VICTORIA)

— Digoxin: symptom control only; narrow window; level 0.5–0.9 ng/mL

— Loop diuretics: symptom/congestion control only — no mortality benefit; use lowest effective dose

1. RAAS inhibition — ARNI preferred over ACEi/ARB:

2. Evidence-based beta-blockers (only three with HFrEF mortality benefit):

3. Mineralocorticoid receptor antagonist (MRA):

4. SGLT2 inhibitor:

Adjuncts when indicated:

Step 3 management: Avoid non-dihydropyridine CCBs (verapamil, diltiazem) in HFrEF — negative inotropes worsen outcomes. Also avoid NSAIDs, thiazolidinediones (pioglitazone), and most antiarrhythmics except amiodarone and dofetilide.

Procedures and Device Therapy

— Indications: LVEF ≤35%, NYHA II–III, on ≥3 months of optimal GDMT, life expectancy >1 year

— Ischemic etiology: also wait ≥40 days post-MI and ≥90 days post-revascularization before implant (allows EF recovery)

— Non-ischemic: same EF/NYHA criteria; DANISH trial showed less mortality benefit but still indicated for guideline-directed primary prevention

— Secondary prevention: survivors of VT/VF arrest or sustained VT with structural disease — regardless of EF

— Strongest indication (Class I): LVEF ≤35% + NYHA II–IV + LBBB with QRS ≥150 ms + sinus rhythm, on GDMT

— Class IIa: QRS 120–149 ms with LBBB, or ≥150 ms non-LBBB

— CRT-D (with defibrillator) typical for EF ≤35%

— Reduces mortality and hospitalization; can produce super-response with EF recovery >50%

— Bridge during 40-day post-MI or 90-day post-revascularization wait, or during early GDMT optimization in newly diagnosed cardiomyopathy

— Ischemic HFrEF with significant CAD and viable myocardium → CABG preferred over PCI (STICH/STICHES — 10-year survival benefit)

— PCI for unsuitable surgical candidates or specific anatomy

— Secondary (functional) MR in HFrEF with persistent severe MR despite GDMT: transcatheter edge-to-edge repair (TEER/MitraClip) per COAPT criteria (LVEF 20–50%, LVESD ≤70 mm, severe MR)

— Severe AS: TAVR or SAVR

— Continuous IV inotropes (milrinone, dobutamine) — palliative or bridge

— LVAD (HeartMate 3) — destination therapy or bridge to transplant

— Orthotopic heart transplant — for select patients <70 with VO2 max <14, refractory symptoms

— Catheter ablation superior to medical rate control for AF + HFrEF (CASTLE-AF) — improves EF, reduces mortality and HF hospitalization

Implantable cardioverter-defibrillator (ICD) — primary prevention:

Cardiac resynchronization therapy (CRT):

Wearable cardioverter-defibrillator (LifeVest):

Revascularization:

Valvular interventions:

Advanced therapies (Stage D):

Atrial fibrillation in HFrEF:

CCS pearl: Before scheduling ICD, document ≥3 months of optimized GDMT and repeat TTE — many patients recover EF >35% with quadruple therapy and no longer need device.

Special Populations — Elderly and Renal/Hepatic Impairment

— Same GDMT applies — age alone is not a contraindication

— Start at lower doses; titrate more slowly

— Watch for: orthostatic hypotension, falls, polypharmacy interactions, cognitive impairment affecting adherence

— ARNI well-tolerated in elderly (PARAGON sub-analyses); SGLT2i particularly beneficial

— Deprescribe medications that no longer benefit (statins in limited life expectancy, aggressive HTN targets)

— Frailty assessment guides advanced therapy candidacy and goals-of-care discussions

— ACEi/ARB/ARNI: continue until eGFR <30 if tolerated; expect 20–30% rise in creatinine at initiation — do NOT stop unless rise exceeds 30% or K >5.5

— MRA: safe to eGFR 30; finerenone (newer non-steroidal MRA) approved for CKD with type 2 diabetes

— SGLT2 inhibitors: initiate down to eGFR 20 (dapagliflozin, empagliflozin); continue even when started until dialysis. Slows CKD progression (DAPA-CKD, EMPA-KIDNEY)

— Loop diuretics: higher doses needed in CKD; switch to torsemide or bumetanide if poor furosemide response (better bioavailability)

— Avoid: NSAIDs, IV contrast when possible, nephrotoxic combinations

— Dietary counseling, loop diuretic optimization

— Patiromer or sodium zirconium cyclosilicate allow continued MRA/ACEi use rather than discontinuation

— Congestive hepatopathy common — elevated AST/ALT, bilirubin, INR from RV failure

— Sacubitril/valsartan: avoid in severe hepatic impairment (Child-Pugh C)

— Carvedilol: highly hepatically metabolized; consider metoprolol succinate

— Spironolactone: caution in cirrhosis (already used for ascites)

Elderly (>75 years):

Chronic kidney disease (CKD) — common in HFrEF (cardiorenal syndrome):

Hyperkalemia management (allows GDMT continuation):

Hepatic impairment:

Step 3 management: Patient on ARNI develops Cr rise from 1.2 to 1.5 (25% increase) and K 4.8 → continue ARNI, recheck in 1–2 weeks. Stopping prematurely loses mortality benefit. Discontinue NSAIDs and recheck volume status.

Board pearl: A mild creatinine bump with GDMT initiation is expected and protective long-term — Step 3 distractors will tempt you to stop the drug.

Special Populations — Pregnancy and Peripartum Cardiomyopathy

— New-onset HFrEF (LVEF <45%) from last month of pregnancy to 5 months postpartum without other identifiable cause

— Risk factors: age >30, multiparity, multiple gestation, preeclampsia, African ancestry

— ~50% recover EF with treatment; risk of recurrence in subsequent pregnancy (especially if EF doesn't normalize)

— Beta-blockers: metoprolol or bisoprolol preferred; avoid atenolol (IUGR)

— Hydralazine + nitrates: safe in pregnancy — substitute for ACEi/ARB/ARNI

— Loop diuretics: use cautiously (placental perfusion); furosemide preferred over torsemide

— Digoxin: safe

— AVOID in pregnancy/lactation: ACEi, ARB, ARNI (renal dysgenesis, oligohydramnios, fetal demise), MRA (antiandrogen — spironolactone), SGLT2i (limited data, avoid), ivabradine, warfarin (1st trimester)

— Anticoagulation if EF <35% or LV thrombus: LMWH preferred

— Multidisciplinary "cardio-obstetric" team

— Vaginal delivery preferred when stable; epidural to blunt sympathetic surge

— Cesarean for obstetric indications or hemodynamic instability

— Once delivered/not breastfeeding → transition to full GDMT (ARNI, beta-blocker, MRA, SGLT2i)

— Continue therapy at least 12 months after EF normalization before considering taper

— Counsel against subsequent pregnancy if EF has not fully recovered (>50%) — high mortality risk

— Etiologies differ: congenital heart disease, viral myocarditis, genetic cardiomyopathies, anthracycline exposure

— Referral to pediatric cardiology essential

Peripartum cardiomyopathy (PPCM):

Pregnancy-safe HF therapy (modified GDMT):

Bromocriptine for PPCM: studied but not standard of care; cabergoline may be used to suppress lactation in severe PPCM (allowing full GDMT postpartum)

Delivery planning:

Postpartum:

Pediatric HFrEF:

Step 3 management: 32-year-old woman 2 months postpartum with dyspnea, EF 25% → start metoprolol succinate + hydralazine/nitrate + furosemide; if not breastfeeding, can use ACEi after cessation; anticoagulate if EF <30% or LV thrombus; counsel against pregnancy until EF recovery documented.

Key distinction: ACEi/ARB/ARNI are lactation-compatible (enalapril, captopril preferred) — but contraindicated during pregnancy.

Complications and Adverse Outcomes

— Sudden cardiac death (SCD): ventricular arrhythmias — primary driver of mortality in HFrEF; rationale for ICD

— Progressive pump failure: worsening symptoms, refractory congestion, end-organ hypoperfusion → Stage D

— Acute decompensated HF (ADHF): rehospitalization within 30 days in ~25% — major quality metric

— Cardiorenal syndrome: types 1 (acute cardiac → renal), 2 (chronic), 4 (chronic CKD → cardiac), 5 (systemic)

— Cardiohepatic syndrome: congestive hepatopathy, "cardiac cirrhosis" in chronic RV failure

— Atrial fibrillation: present in 30–40% of HFrEF; worsens symptoms, raises stroke risk

— Ventricular tachycardia/fibrillation: scar substrate from prior MI or cardiomyopathy

— LV thrombus: especially with EF <30% or apical akinesis — anticoagulate ×3–6 months

— Functional MR/TR: annular dilation worsens HF in feedback loop

— Cachexia: muscle wasting, sarcopenia — poor prognostic sign

— Depression, anxiety, cognitive impairment ("cardiac cachexia of the brain")

— ACEi/ARB/ARNI: hyperkalemia, AKI, hypotension, angioedema (ARNI > ACEi for angioedema if sequential), cough (ACEi only — bradykinin)

— Beta-blockers: bradycardia, AV block, bronchospasm (less with cardioselective), fatigue, hypotension, glucose masking in diabetes

— MRA: hyperkalemia (most important), gynecomastia/mastodynia with spironolactone, AKI

— SGLT2i: euglycemic DKA (especially perioperative — hold 3 days before surgery), genital mycotic infections, volume depletion, rare Fournier gangrene, lower-extremity amputation risk (canagliflozin)

— Loop diuretics: hypokalemia, hypomagnesemia, hyponatremia, ototoxicity (high-dose IV), prerenal AKI, gout flares

— Digoxin toxicity: nausea, visual halos, arrhythmias — narrower window in elderly and CKD

— Hydralazine: drug-induced lupus, reflex tachycardia

Disease-related complications:

Therapy-related adverse effects:

Board pearl: 30-day readmission for HF is a CMS-tracked quality metric — early post-discharge clinic visit (within 7–14 days), medication reconciliation, weight monitoring, and clear sick-day rules reduce readmissions.

Step 3 management: Post-discharge HFrEF patient with K 5.6 on spironolactone + lisinopril → hold MRA, dietary counseling, recheck in 1 week; consider potassium binder (patiromer) to preserve GDMT rather than permanent discontinuation.

When to Escalate Care — ICU, Consult, Inpatient Triage

— Resting dyspnea, orthopnea unable to lie flat

— Hypotension (SBP <90) with cool extremities, altered mentation → cardiogenic shock

— Sustained ventricular arrhythmias, syncope

— New or worsening chest pain suggesting ACS

— Severe hyperkalemia (K >6) with ECG changes

— Rapid weight gain (>5 lb in 3 days) with severe symptoms refusing oral diuretic escalation

— Suspected ICD shock (single or multiple)

— Acute kidney injury with oliguria

— Inotropes required

— NYHA III–IV/persistently elevated natriuretic peptides

— End-organ dysfunction

— EF ≤35%

— Defibrillator shocks

— Hospitalizations recurrent

— Edema despite escalating diuretics

— Low systolic BP/high heart rate

— Prognostic medication intolerance

— Floor: stable vitals, responsive to IV diuretics, no inotrope need

— Step-down/telemetry: arrhythmias, escalating diuretic needs, IV vasodilators (nitroglycerin)

— ICU: cardiogenic shock, inotropes/pressors, mechanical ventilation, mechanical circulatory support (IABP, Impella, VA-ECMO)

Outpatient red flags requiring same-day ED referral:

Specialist referral triggers — "I-NEED-HELP" criteria for advanced HF referral:

Inpatient triage of decompensated HF:

Cardiology consultation in clinic: new HFrEF diagnosis, EF <35% with device candidacy, refractory symptoms despite GDMT, valvular intervention candidacy, AF for rhythm control, transplant/LVAD evaluation

Electrophysiology consult: ICD/CRT implantation, ablation for AF or VT, ICD shocks

Palliative care consult: any Stage D patient, recurrent hospitalizations, symptom burden, goals-of-care clarification — integrate early, not only at end of life

CCS pearl: In the simulated CCS case, escalating to ED or admit is the right call when a patient presents to clinic with resting tachypnea, SBP <90, cool extremities, or sustained arrhythmia. Order IV access, telemetry, cardiac biomarkers, BNP, CXR, ECG, ABG/lactate immediately, then transfer.

Step 3 management: Patient with HFrEF and new shock from ICD with frequent VT episodes → admit, EP consult, optimize antiarrhythmics (amiodarone), consider VT ablation. Do not simply increase outpatient meds.

Key Differentials — Same-Category Causes (Other HF Subtypes)

— LVEF ≥50% with HF signs/symptoms and elevated filling pressures

— Demographics: older, female, obese, HTN, AF, CKD

— Diagnostic scores: H2FPEF, HFA-PEFF

— Treatment now includes SGLT2 inhibitors (Class I — EMPEROR-Preserved, DELIVER) as cornerstone; MRA reasonable; ARNI Class IIb; loop diuretics for congestion

— Key distinction: in HFpEF, beta-blockers and ACEi have NOT shown mortality benefit — manage comorbidities (HTN, AF, obesity, OSA)

— Treat like HFrEF — ARNI, beta-blocker, MRA, SGLT2i all reasonable (Class IIa/IIb)

— Prior EF ≤40%, now >40% on GDMT

— Continue all GDMT indefinitely — TRED-HF showed relapse in 40% within 6 months when therapy withdrawn

— Causes: left heart failure (most common), pulmonary hypertension (groups 1–5), pulmonary embolism, RV infarct, arrhythmogenic RV cardiomyopathy

— Findings: elevated JVP, hepatomegaly, ascites, peripheral edema with clear lungs

— Severe anemia, thyrotoxicosis, AV fistula (dialysis), beriberi (thiamine deficiency), Paget disease, pregnancy, sepsis, obesity

— Warm extremities, wide pulse pressure, bounding pulses

— Treat underlying cause

— Mimics RV failure with elevated JVP, Kussmaul sign, pericardial knock, square-root sign on cath

— Causes: post-cardiac surgery, post-XRT, TB, viral

— Key distinction: echo shows normal EF and respiratory variation in mitral inflow; pericardiectomy is curative

— Preserved EF early (mimics HFpEF) but progresses to reduced EF

— Bilateral carpal tunnel, low-voltage ECG with thick walls = think amyloid

Heart failure with preserved ejection fraction (HFpEF):

Heart failure with mildly reduced EF (HFmrEF, 41–49%):

Heart failure with improved EF (HFimpEF):

Right heart failure:

High-output heart failure:

Constrictive pericarditis:

Restrictive cardiomyopathy (amyloid, sarcoid, hemochromatosis):

Board pearl: A patient with prior HFrEF whose EF recovered to 50% on quadruple therapy is HFimpEF — DO NOT stop meds. This is a high-yield Step 3 trap.

Key Differentials — Other-Category Causes of Dyspnea/Edema

— COPD/asthma exacerbation: wheezing, prolonged expiration, smoking history; BNP may be mildly elevated from RV strain (cor pulmonale)

— Pneumonia: fever, productive cough, focal consolidation, leukocytosis

— Pulmonary embolism: acute, pleuritic, hypoxia disproportionate to exam; D-dimer, CTPA; consider in unilateral leg swelling

— Pulmonary hypertension: RV strain on ECG, dilated PA on CT, requires RHC

— Interstitial lung disease: dry cough, Velcro crackles, HRCT findings

— Pleural effusion from non-cardiac causes

— Nephrotic syndrome: proteinuria >3.5 g/day, hypoalbuminemia, periorbital and lower extremity edema; UA with foamy urine

— CKD with volume overload: elevated Cr, hyperkalemia, acidosis

— Distinguish via UA, urine protein/Cr, albumin, BNP (often elevated in renal disease but TTE normal)

— Cirrhosis with ascites: stigmata of liver disease, low albumin, elevated INR, SAAG >1.1

— Budd-Chiari: acute hepatic vein thrombosis

— Bilateral pitting edema worse at end of day, varicose veins, hemosiderin staining, normal JVP and lungs

— Non-pitting, often unilateral, dorsum of foot involvement (Stemmer sign)

— Calcium channel blockers (amlodipine — peripheral edema without volume overload)

— NSAIDs (sodium retention, can precipitate true HF)

— Thiazolidinediones (pioglitazone) — contraindicated in NYHA III–IV HF

— Pregabalin/gabapentin — peripheral edema

— Severe anemia causes high-output state mimicking HF

— Hyperthyroidism: AF, tachycardia, weight loss, heat intolerance

— Hypothyroidism: bradycardia, weight gain, periorbital edema, pericardial effusion

— Common HFrEF comorbidity worsening symptoms

Pulmonary causes of dyspnea:

Renal causes of edema:

Hepatic causes:

Venous insufficiency:

Lymphedema:

Medication-induced:

Anemia/thyroid:

Obesity hypoventilation/OSA:

Step 3 management: Patient with bilateral lower extremity edema, normal JVP, normal BNP, normal TTE, on amlodipine 10 mg → stop amlodipine, edema resolves. Not heart failure. Don't initiate GDMT.

Key distinction: A normal BNP/NT-proBNP with normal TTE effectively rules out HFrEF as the cause of dyspnea — pursue alternative diagnosis.

Secondary Prevention, Discharge Medications, Long-Term Plan

— ARNI (or ACEi/ARB) at tolerated dose

— Beta-blocker (carvedilol, metoprolol succinate, or bisoprolol) — initiated only when euvolemic

— MRA if K ≤5.0, eGFR ≥30

— SGLT2 inhibitor — virtually all HFrEF patients

— Loop diuretic at maintenance dose (typically lower than inpatient dose)

— Statin if ASCVD, diabetes, or LDL ≥190

— Antiplatelet/anticoagulant as indicated (ASA for CAD; DOAC for AF; warfarin if mechanical valve or LV thrombus)

— Influenza vaccine annually, pneumococcal per schedule, COVID-19, RSV per current guidelines

— BP target: <130/80 (achieved largely through GDMT)

— Diabetes: A1c <7% in most; prefer SGLT2i and GLP-1 RAs over sulfonylureas/TZDs

— Lipid management: high-intensity statin for ASCVD secondary prevention

— Smoking cessation, alcohol limitation (<1–2 drinks/day; abstinence if alcohol-induced cardiomyopathy), drug cessation

— Weight management: target BMI 18.5–30

— Sleep apnea: screen and treat with CPAP if OSA

— Sodium restriction: moderate (<2–3 g/day); strict <2 g if congestion-prone

— Fluid restriction: 1.5–2 L/day if hyponatremic or persistent congestion (not all patients)

— Daily weights at same time each morning; report >2 lb in 1 day or >5 lb in 1 week

— Exercise: cardiac rehab improves outcomes (Class I) — refer all HFrEF patients

— Sick-day rules: hold SGLT2i, ACEi/ARB/ARNI, MRA during acute illness with poor PO; resume when recovered

— NSAIDs, COX-2 inhibitors, thiazolidinediones, non-dihydropyridine CCBs (with severe LV dysfunction), most class I antiarrhythmics, cilostazol, decongestants (pseudoephedrine)

Discharge medication checklist after HFrEF hospitalization:

Risk factor modification:

Lifestyle counseling:

Avoid these medications:

Step 3 management: Discharge transition is the highest-risk window — schedule follow-up within 7–14 days, medication reconciliation, dedicated HF nurse touchpoint if available. Provide written action plan with weight log.

Board pearl: Cardiac rehab is Class I for HFrEF and Step 3 will test that you actually order it — improves functional capacity, reduces hospitalization, lowers depression.

Follow-Up, Monitoring, and Counseling

— Newly diagnosed or recently hospitalized: every 1–2 weeks during GDMT titration

— Stable on optimized GDMT: every 3–6 months

— Advanced HF (Stage D): monthly or more

— HF nurse/clinic touchpoints between physician visits reduce readmissions

— Symptoms: NYHA class, orthopnea, PND, edema, fatigue, syncope

— Adherence: medications, diet, fluid, weights

— Triggers: dietary indiscretion, missed meds, infection, new arrhythmia

— Exam: BP (sit and stand), HR, weight, JVP, lungs, edema, perfusion

— Labs: BMP (Na, K, Cr) within 1–2 weeks of any titration; periodic CBC, magnesium, iron studies annually

— NT-proBNP trends can guide therapy in select patients (GUIDE-IT trial mixed; reasonable adjunct, not standalone)

— Repeat TTE 3–6 months after GDMT optimization to reassess EF for device candidacy and HFimpEF reclassification

— Sooner repeat if clinical deterioration or new event

— Up-titrate every 1–2 weeks if BP and HR allow (SBP ≥90, HR ≥55, K <5.0, Cr stable)

— Target doses preferred but maximally tolerated doses still benefit

— Do not abruptly stop beta-blockers (rebound), ARNI (decompensation risk)

— Recognize symptoms of worsening HF

— Daily weight log; threshold for calling clinic (>2 lb/day, >5 lb/week, new orthopnea/edema)

— Diuretic "self-adjustment" plans for stable patients (extra furosemide dose for early congestion)

— Sick-day rules for SGLT2i, RAAS inhibitors, MRA

— Vaccinations, exercise, sodium/fluid goals

— Class I recommendation; covered by Medicare for HFrEF NYHA II–III

— 36 sessions over 12 weeks; supervised exercise + education

— Depression in 20–40% of HFrEF — PHQ-9 at intervals; treat (SSRIs preferred; avoid TCAs due to QT and proarrhythmia)

Visit cadence:

Each visit (CCS-style template):

Imaging follow-up:

Medication titration principles:

Patient education essentials:

Cardiac rehab:

Mental health screening:

Step 3 management: Patient stable for 6 months on quadruple therapy with EF improved from 25 to 45% → continue all therapy, repeat TTE annually, continue every 6-month visits. Do not discontinue meds despite EF improvement.

Board pearl: Re-imaging at 3–6 months post-GDMT defines who still needs an ICD — a meaningful number of patients recover EF >35% and avoid device implant.

Ethical, Legal, and Patient Safety Considerations

— HFrEF has a worse 5-year survival than many cancers; early goals-of-care discussions are essential but often deferred

— Address: code status, ICD deactivation preferences, hospitalization preferences, hospice eligibility

— ICD deactivation at end of life: not euthanasia; reprogramming to disable shocks while pacing function remains — clarify in advance directives. Step 3 favorite ethical scenario.

— Hospice eligibility: NYHA IV despite optimal therapy with life expectancy ≤6 months

— ICD/CRT implantation: discuss procedural risks, lifelong device monitoring, shock experiences, end-of-life deactivation before implantation

— LVAD destination therapy: complex consent involving caregiver burden, stroke/bleeding risk, driveline infection, end-of-life considerations

— Heart transplant: lifelong immunosuppression, biopsy surveillance, malignancy risk

— Medication reconciliation at every transition (admission, discharge, clinic) — discrepancies common, especially with diuretic and potassium-binder titration

— Discharge summary to PCP within 48 hours; explicit titration plan

— Post-discharge phone call within 48–72 hours and clinic visit within 7–14 days reduce readmission

— Teach-back method for discharge instructions in patients with low health literacy

— Diuretics (electrolyte derangement, falls in elderly)

— Anticoagulants (bleeding)

— Digoxin (narrow therapeutic window; avoid in CKD without level monitoring)

— Drug interactions: ARNI + ACEi (angioedema risk — never co-administer), MRA + ACEi/ARB (hyperkalemia), digoxin + amiodarone (raises digoxin levels)

— Recent ICD shock or syncope — most states restrict driving (commercial: 6 months; private: typically 3–6 months after VT/VF event)

— Document counseling on driving restrictions

— Black patients underutilize GDMT and advanced therapies; A-HeFT-based hydralazine/nitrate + standard GDMT specifically benefits self-identified Black NYHA III–IV patients

— Address socioeconomic barriers (medication cost, transportation, food insecurity)

Advance care planning and goals of care:

Informed consent edge cases:

Transitions of care — highest-risk window:

Patient safety high-risk medications:

Mandatory reporting and driving:

Health equity:

Step 3 management: Patient with NYHA IV HFrEF, two recent ICD shocks, declining home function → palliative care consult, discuss ICD deactivation as part of comfort-focused plan; offer hospice if life expectancy ≤6 months.

Board pearl: ICD deactivation at end of life is ethically and legally appropriate — withholding/withdrawing burdensome therapy, not euthanasia.

High-Yield Associations and Rapid-Fire Clinical Facts

Four-pillar mortality benefit: ARNI + beta-blocker + MRA + SGLT2i → ~73% RRR vs. minimal therapy; start all four within days–weeks

ARNI > ACEi: PARADIGM-HF showed 20% mortality reduction switching from enalapril to sacubitril/valsartan

36-hour washout: required when switching ACEi → ARNI to avoid angioedema; no washout from ARB

Only three beta-blockers in HFrEF: carvedilol, metoprolol succinate (not tartrate), bisoprolol

SGLT2i benefit independent of diabetes (DAPA-HF, EMPEROR-Reduced) — initiate even in non-diabetics

ICD timing: wait 40 days post-MI, 90 days post-revascularization, 3 months on GDMT

CRT works best: LBBB + QRS ≥150 ms + LVEF ≤35% + NYHA II–IV

Hydralazine + nitrate: Class I in self-identified Black patients NYHA III–IV on GDMT; also if ACEi/ARB/ARNI contraindicated

Iron deficiency: IV ferric carboxymaltose improves symptoms even without anemia (ferritin <100 or 100–300 with TSAT <20%)

AF ablation in HFrEF: CASTLE-AF — superior to rate control, reduces mortality and HF hospitalization

TEER (MitraClip): for severe secondary MR with EF 20–50% on optimal GDMT (COAPT criteria)

STICH/STICHES: CABG superior to medical therapy alone for ischemic HFrEF at 10 years

Amyloid clues: bilateral carpal tunnel syndrome, low-voltage ECG with thick LV walls, pseudo-infarct pattern, autonomic dysfunction

LV thrombus: anticoagulate 3–6 months when EF <30% with apical akinesis or documented thrombus

Avoid in HFrEF: non-DHP CCBs (verapamil/diltiazem), NSAIDs, thiazolidinediones, most class I antiarrhythmics

Loop diuretics: symptom benefit only — no mortality benefit; use lowest effective dose

Digoxin: target level 0.5–0.9 ng/mL; reduces hospitalization, no mortality benefit

Cardiac rehab: Class I in HFrEF NYHA II–III

30-day readmission rate for HF: ~25% — CMS quality metric driving early follow-up requirement

VO2 max <14 mL/kg/min = consider transplant evaluation

HFimpEF (recovered EF): continue GDMT indefinitely — TRED-HF showed 40% relapse with withdrawal

Board pearl: When a Step 3 stem says "EF improved from 25% to 50% with therapy," the answer is virtually always continue all medications.

Board Question Stem Patterns

— Stem: "65M with newly diagnosed HFrEF (EF 25%) discharged 2 weeks ago on lisinopril 10 mg and carvedilol 6.25 mg BID. BP 122/78, HR 72, K 4.2, Cr 1.1, eGFR 65. NYHA II symptoms."

— Best next step: switch lisinopril to sacubitril/valsartan after 36-hour washout, add spironolactone, add dapagliflozin — and up-titrate over 4–6 weeks

— Stem: ARNI started, Cr rises from 1.0 to 1.3 (30% rise), K 4.7, no symptoms

— Answer: continue ARNI, recheck in 1–2 weeks — do not discontinue

— Stem: 60M with anterior STEMI 3 weeks ago, EF 28%, NYHA II, on GDMT

— Answer: continue GDMT for ≥40 days post-MI and 3 months total, then repeat TTE; if EF still ≤35%, refer for ICD

— Stem: HFrEF patient with EF improved from 25 to 50%, asymptomatic, "asks about stopping medications"

— Answer: continue all GDMT indefinitely (TRED-HF relapse risk)

— Stem: HFrEF with new chronic AF, what rate control agent?

— Answer: metoprolol succinate or digoxin — NOT verapamil or diltiazem

— Stem: elderly with "HFpEF," bilateral carpal tunnel release, low-voltage ECG, thick LV walls

— Answer: SPEP/UPEP/free light chains first (rule out AL), then PYP scan for ATTR

— Stem: postpartum dyspnea, EF 30%

— Answer: peripartum cardiomyopathy; metoprolol + hydralazine/nitrate + furosemide; avoid ACEi/ARB/ARNI/MRA/SGLT2i in pregnancy; counsel against subsequent pregnancy if EF not recovered

— Stem: HFrEF EF 30%, NYHA III, LBBB with QRS 160 ms, on GDMT 3 months

— Answer: CRT-D

— Stem: stable HFrEF clinic visit

— Answer: refer to cardiac rehab — Class I, often the "missed" correct answer

— Stem: NYHA IV, recurrent ICD shocks, hospice candidate

— Answer: discuss ICD deactivation as part of comfort-focused care

Pattern 1 — The post-discharge optimization vignette:

Pattern 2 — The mild creatinine bump trap:

Pattern 3 — ICD timing:

Pattern 4 — HFimpEF withdrawal trap:

Pattern 5 — Avoid in HFrEF:

Pattern 6 — Amyloid detection:

Pattern 7 — Pregnancy HF:

Pattern 8 — CRT eligibility:

Pattern 9 — Cardiac rehab order:

Pattern 10 — End-of-life ICD:

Step 3 management: When in doubt on Step 3, the answer favors adding the missing pillar of GDMT or up-titrating, scheduling close follow-up, and never abruptly stopping evidence-based therapy.

One-Line Recap

HFrEF outpatient care = simultaneously initiate and rapidly titrate the four pillars of GDMT (ARNI, evidence-based beta-blocker, MRA, SGLT2 inhibitor) toward target doses while monitoring volume, potassium, renal function, and EF response, then layer on device therapy (ICD ± CRT) at the 3-month mark for persistent EF ≤35%.

Board pearl: If you remember only one thing for Step 3 HFrEF questions: the right answer almost always involves adding the missing pillar, up-titrating an existing one, or scheduling closer follow-up — rarely stopping a medication.

Quadruple therapy first, fast: start all four classes within 2 weeks; up-titrate every 1–2 weeks; reach maximally tolerated doses within 3–6 months; mortality benefit accrues within 30 days.

Don't stop GDMT for predictable side effects: mild Cr rise (<30%), K up to 5.0–5.4, mild hypotension without symptoms — treat the cause (NSAIDs, volume status, dietary K) rather than abandoning therapy; manage hyperkalemia with potassium binders to preserve MRA and ACEi/ARNI.

Reimage and reassess at 3–6 months: repeat TTE determines ICD candidacy (EF still ≤35%), CRT candidacy (LBBB ≥150 ms), HFimpEF reclassification (continue GDMT indefinitely), and need for advanced therapy referral via I-NEED-HELP criteria.

Transition of care is the danger zone: schedule follow-up within 7–14 days of discharge, medication reconciliation, sick-day rules, daily weights, cardiac rehab referral (Class I), vaccinations, and early goals-of-care/ICD deactivation conversations for Stage D — these are the Step 3-flavored items that prevent the 30-day readmission and align longitudinal outpatient HF management with the modern guideline standard.